BenfoTeam
Placebo-Controlled Trial to Evaluate the Safety & Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease
Purpose
To evaluate the safety and efficacy of Benfotiamine in patients with Early Alzheimer’s Disease (MCI due to AD or Early A.)
Who can participate
To participate in this study, the patient:
- Must be between the ages of 50-89 at screening visit
- MMSE score between 20-30 (inclusive)
- MoCA score < 26
- CDR global score of 0.5 or 1.0; memory score 0.5 or higher at screening
- Positive plasma biomarker testing result
- Must have a study partner who can be available at all in-clinic & remote visits & has frequent interaction w/pt
- Females must be post-menopausal > 1 year or surgically sterile > 6 months
